Indian pharma companies eye larger share of US cancer generics market

Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures in the generics space in the US

Indian drug firms are eyeing a larger share of the $145 billion US oncology market, which is growing at an 11 per cent compound annual growth rate (CAGR).

 

In the past few months, several Indian drug firms have received US Food and Drug Administration (FDA) approvals for oncology generics, marking a steady rise in complex generic and biosimilar drug entries into the US market.

 

The US oncology market size was valued at $145.52 billion in 2024 and is projected to hit around $416.93 billion by 2034, expanding at a CAGR of 11.1 per cent over the forecast period from 2025